Page 114 - Bio Engineering Approaches to Cancer Diagnosis and Treatment

112 CHAPTER 4 Immunotherapy

[72] K. Palucka, J. Banchereau, Dendritic-cell-based therapeutic cancer vaccines, Immunity
39 (1) (2013) 38–48.
[73] Q. Song, C.D. Zhang, X.H. Wu, Therapeutic cancer vaccines: From initial findings to
prospects, Immunol. Lett. 196 (2018) 11–21.
[74] U. Sahin, E. Derhovanessian, M. Miller, B.P. Kloke, P. Simon, M. Löwer, T. Omokoko,
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity
against cancer, Nature 547 (7662) (2017) 222–226.
[75] M.S. Mitchell, J. Kan-Mitchell, R.A. Kempf, W. Harel, H. Shau, S. Lind, Active specific
immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant,
Can. Res. 48 (20) (1988) 5883–5893.
[76] A.R. Aldous, J.Z. Dong, Personalized neoantigen vaccines: A new approach to cancer
immunotherapy, Bioorg. Med. Chem. 26 (10) (2018) 2842–2849.
[77] S.A. Rosenberg, J.C. Yang, N.P. Restifo, Cancer immunotherapy: moving beyond current
vaccines, Nat. Med. 10 (9) (2004) 909.
[78] S.H. van der Burg, R. Arens, F. Ossendorp, T. van Hall, C.J. Melief, Vaccines for estab-
lished cancer: overcoming the challenges posed by immune evasion, Nat. Rev. Can. 16
(4) (2016) 219–233.
[79] J. Banchereau, R.M. Steinman, Dendritic cells and the control of immunity, Nature 392
(6673) (1998) 245–252.
[80] R.M. Steinman, The dendritic cell system and its role in immunogenicity, Ann. Rev. Im-
munol. 9 (1) (1991) 271–296.
[81] B. Mukherji, N.G. Chakraborty, S. Yamasaki, T. Okino, H. Yamase, J.R. Sporn, J. Mee-
han, Induction of antigen-specific cytolytic T cells in situ in human melanoma by im-
munization with synthetic peptide-pulsed autologous antigen presenting cells, Proc. Nat.
Acad. Sci. 92 (17) (1995) 8078–8082.
[82] A. Heiser, M.A. Maurice, D.R. Yancey, N.Z. Wu, P. Dahm, S.K. Pruitt, J. Vieweg, Induc-
tion of polyclonal prostate cancer-specific CTL using dendritic cells transfected with
amplified tumor RNA, J. Immunol. 166 (5) (2001) 2953–2960.
[83] S.K. Nair, M. Morse, D. Boczkowski, R.I. Cumming, L. Vasovic, E. Gilboa, H.K. Lyerly,
Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous
tumor RNA-transfected dendritic cells, Ann. Surg. 235 (4) (2002) 540–556.
[84] C. Condon, S.C. Watkins, C.M. Celluzzi, K. Thompson, L.D. Falo, DNA–based immu-
nization by in vivo transfection of dendritic cells, Nat. Med. 2 (10) (1996) 1122–1130.
[85] D. Ridgway, The first 1000 dendritic cell vaccinees, Can. Investig. 21 (6) (2003) 873–886.
[86] G. Parmiani, C. Castelli, P. Dalerba, R. Mortarini, L. Rivoltini, F.M. Marincola, A. An-
ichini, Cancer immunotherapy with peptide-based vaccines: what have we achieved?
Where are we going? J. Nat. Can. Inst. 94 (11) (2002) 805–818.
[87] C.L. Slingluff, G.R. Petroni, K.A. Chianese-Bullock, M.E. Smolkin, S. Hibbitts, C. Mur-
phy, J.W. Patterson, Immunologic and clinical outcomes of a randomized phase II trial of
two multipeptide vaccines for melanoma in the adjuvant setting, Clin. Can. Res. 13 (21)
(2007) 6386–6395.
[88] R. Rampling, S. Peoples, P.J. Mulholland, A. James, O. Al-Salihi, C.J. Twelves, J. Lind-
ner, A cancer research UK first time in human phase I trial of IMA950 (novel multipep-
tide therapeutic vaccine) in patients with newly diagnosed glioblastoma, Clin. Can. Res.
22 (19) (2016) 4776–4785.
[89] H.M. Maeng, J.A. Berzofsky, Strategies for developing and optimizing cancer vaccines,
F1000 Res. 8 (2019).